Administration of a dual CXCR1/2-targeted antagonistic peptide alone inhibited the growth of PTEN-deficient but not PTEN-expressing DU145 and PC3 xenograft tumours, consistent with our prior and current demonstration of CXCL8 functioning as a key survival factor in this genetic context (21). The gene discussed is PTEN; the disease is neoplasm.